Tariquidar
| Title | Journal |
|---|---|
| P-Glycoprotein on Blood-Brain Barrier Plays a Vital Role in Fentanyl Brain Exposure and Respiratory Toxicity in Rats. | Toxicological sciences : an official journal of the Society of Toxicology 20180701 |
| Increasing nerve agent treatment efficacy by P-glycoprotein inhibition. | Chemico-biological interactions 20161125 |
| Inhibition of P-glycoprotein Gene Expression and Function Enhances Triptolide-induced Hepatotoxicity in Mice. | Scientific reports 20150101 |
| Behavioral effects and central nervous system levels of the broadly available κ-agonist hallucinogen salvinorin A are affected by P-glycoprotein modulation in vivo. | The Journal of pharmacology and experimental therapeutics 20120601 |
| Structure-activity relationships, ligand efficiency, and lipophilic efficiency profiles of benzophenone-type inhibitors of the multidrug transporter P-glycoprotein. | Journal of medicinal chemistry 20120412 |
| [Evaluation of P-glycoprotein mediated in vitro loperamide biliary excretion with sandwich-cultured rat hepatocytes model]. | Yao xue xue bao = Acta pharmaceutica Sinica 20120401 |
| Alteration in P-glycoprotein functionality affects intrabrain distribution of quinidine more than brain entry-a study in rats subjected to status epilepticus by kainate. | The AAPS journal 20120301 |
| Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data. | Clinical pharmacology and therapeutics 20120201 |
| A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer. | European journal of nuclear medicine and molecular imaging 20120101 |
| Genetic knockdown and pharmacological inhibition of parasite multidrug resistance transporters disrupts egg production in Schistosoma mansoni. | PLoS neglected tropical diseases 20111201 |
| Increasing oxime efficacy by blood-brain barrier modulation. | Toxicology letters 20110925 |
| Synthesis and structure-activity evaluation of isatin-β-thiosemicarbazones with improved selective activity toward multidrug-resistant cells expressing P-glycoprotein. | Journal of medicinal chemistry 20110825 |
| Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin. | Journal of medicinal chemistry 20110728 |
| Solid phase synthesis of tariquidar-related modulators of ABC transporters preferring breast cancer resistance protein (ABCG2). | Bioorganic & medicinal chemistry letters 20110615 |
| A novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrier. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20110615 |
| The third-generation P-glycoprotein inhibitor tariquidar may overcome bacterial multidrug resistance by increasing intracellular drug concentration. | The Journal of antimicrobial chemotherapy 20110401 |
| Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP). | Bioorganic & medicinal chemistry 20110315 |
| A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110201 |
| Synthesis and in vivo evaluation of ¹⁸F-fluoroethyl GF120918 and XR9576 as positron emission tomography probes for assessing the function of drug efflux transporters. | Bioorganic & medicinal chemistry 20110115 |
| Specific inhibitors of the breast cancer resistance protein (BCRP). | ChemMedChem 20100903 |
| Synthesis and evaluation of [11C]XR9576 to assess the function of drug efflux transporters using PET. | Annals of nuclear medicine 20100601 |
| Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET. | European journal of nuclear medicine and molecular imaging 20100501 |
| P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20100401 |
| Assessment of regional differences in tariquidar-induced P-glycoprotein modulation at the human blood-brain barrier. | Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20100301 |
| Uptake and binding of the serotonin 5-HT1A antagonist [18F]-MPPF in brain of rats: effects of the novel P-glycoprotein inhibitor tariquidar. | NeuroImage 20100115 |
| Novel lead for potent inhibitors of breast cancer resistance protein (BCRP). | Bioorganic & medicinal chemistry letters 20100101 |
| A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20091201 |
| Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. | Journal of controlled release : official journal of the Controlled Release Society 20090521 |
| A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090515 |
| Synthesis and biological evaluation of a small molecule library of 3rd generation multidrug resistance modulators. | Bioorganic & medicinal chemistry 20090315 |
| Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar. | Journal of medicinal chemistry 20090226 |
| Functional and energetic characterization of P-gp-mediated doxorubicin transport in rainbow trout (Oncorhynchus mykiss) hepatocytes. | Comparative biochemistry and physiology. Toxicology & pharmacology : CBP 20090101 |
| Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice. | Journal of experimental & clinical cancer research : CR 20090101 |
| Tariquidar, a selective P-glycoprotein inhibitor, does not potentiate loperamide's opioid brain effects in humans despite full inhibition of lymphocyte P-glycoprotein. | Anesthesiology 20081201 |
| Resistance to antiepileptic drugs and expression of P-glycoprotein in two rat models of status epilepticus. | Epilepsy research 20081101 |
| Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20080801 |
| Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice. | Journal of cancer research and clinical oncology 20080501 |
| Glutamate is critically involved in seizure-induced overexpression of P-glycoprotein in the brain. | Neuropharmacology 20080501 |
| Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). | Biochemical pharmacology 20080315 |
| Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors. | Bioorganic & medicinal chemistry 20080301 |
| Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. | Bioorganic & medicinal chemistry 20080101 |
| Region-specific overexpression of P-glycoprotein at the blood-brain barrier affects brain uptake of phenytoin in epileptic rats. | The Journal of pharmacology and experimental therapeutics 20070701 |
| In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2). | Bioorganic & medicinal chemistry 20070601 |
| Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein. | Tuberculosis (Edinburgh, Scotland) 20070501 |
| Development of a humanized in vitro blood-brain barrier model to screen for brain penetration of antiepileptic drugs. | Epilepsia 20070301 |
| Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. | Neuropharmacology 20070201 |
| Multidrug-resistance gene 1-type p-glycoprotein (MDR1 p-gp) inhibition by tariquidar impacts on neuroendocrine and behavioral processing of stress. | Psychoneuroendocrinology 20070101 |
| In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity at CYP-450. | Bioorganic & medicinal chemistry 20061201 |
| Quantification of serotonin 5-HT1A receptors in monkey brain with [11C](R)-(-)-RWAY. | Synapse (New York, N.Y.) 20061201 |
| The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity. | Clinical pharmacology and therapeutics 20060901 |
| Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. | Current opinion in pharmacology 20060801 |
| Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier. | The Journal of pharmacology and experimental therapeutics 20060601 |
| Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia. | Nature neuroscience 20060401 |
| Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. | Epilepsia 20060401 |
| Structure-activity relationships of a series of tariquidar analogs as multidrug resistance modulators. | Bioorganic & medicinal chemistry 20060301 |
| Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. | Cancer 20050815 |
| Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. | Cancer biology & therapy 20050801 |
| The coupling mechanism of P-glycoprotein involves residue L339 in the sixth membrane spanning segment. | FEBS letters 20050718 |
| Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome. | Best practice & research. Clinical haematology 20041201 |
| P-glycoprotein retains function when reconstituted into a sphingolipid- and cholesterol-rich environment. | Journal of lipid research 20041001 |
| Ex vivo reversal of chemoresistance by tariquidar (XR9576). | Anti-cancer drugs 20041001 |
| Inhibition of glucosylceramide synthase does not reverse drug resistance in cancer cells. | The Journal of biological chemistry 20040924 |
| Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. | European journal of cancer (Oxford, England : 1990) 20040301 |
| Pheophorbide a is a specific probe for ABCG2 function and inhibition. | Cancer research 20040215 |
| Pumping of drugs by P-glycoprotein: a two-step process? | The Journal of pharmacology and experimental therapeutics 20031201 |
| The histone deacetylase inhibitor FK228 preferentially enhances adenovirus transgene expression in malignant cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20031101 |
| Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. | Clinical cancer research : an official journal of the American Association for Cancer Research 20030201 |
| In vitro prevention of the emergence of multidrug resistance in a pediatric rhabdomyosarcoma cell line. | Clinical cancer research : an official journal of the American Association for Cancer Research 20011001 |
| In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. | Cancer research 20010115 |